Pulse Biosciences (NASDAQ:PLSE) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Pulse Biosciences (NASDAQ:PLSE) from a hold rating to a sell rating in a research note published on Saturday morning.

PLSE has been the topic of a number of other reports. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Canaccord Genuity Group began coverage on shares of Pulse Biosciences in a research report on Thursday, June 4th. They set a “buy” rating and a $32.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Pulse Biosciences presently has an average rating of “Moderate Buy” and an average target price of $41.00.

Pulse Biosciences Price Performance

PLSE opened at $41.51 on Friday. The business has a 50 day moving average price of $29.35 and a two-hundred day moving average price of $23.90. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -35.18 and a beta of 1.61. Pulse Biosciences has a 1-year low of $12.56 and a 1-year high of $45.90.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The firm had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. Pulse Biosciences had a negative return on equity of 100.22% and a negative net margin of 6,755.78%. Equities analysts expect that Pulse Biosciences will post -1.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its holdings in shares of Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Pulse Biosciences by 13.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after purchasing an additional 619 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in Pulse Biosciences during the 2nd quarter worth about $158,000. Finally, Brevan Howard Capital Management LP acquired a new stake in Pulse Biosciences during the 2nd quarter worth about $215,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.